Melatonin inhibitory effect on cAMP accumulation in the chick retina development.
During vertebrate neurodevelopment, neuritogenesis and synaptogenesis are modulated by intracellular cAMP rises. Melatonin, which is implicated in neuronal differentiation, mainly inhibits this pathway. Here, an investigation about the profile of this effect during the vertebrate neurodevelopment is reported. In the embryonic chick retinas at days 8, 12, 14, 16 and at 2 days post-hatched (E8, E12, E14, E16 and PH), those control embryonic retinas incubated only with the phosphodiesterase inhibitor at days corresponding to commencement of neuronal differentiation (E8, E12) and PH, presented cAMP levels inhibited by melatonin. While the cAMP accumulation stimulated by forskolin was inhibited in the embryonic retinas at all testing days. Neither the unselective antagonist N-acetyl-2-benziltryptamine (luzindole) nor the selective Mel(1b) antagonist 4-phenyl-2-propionamidotetralin (4-P-PDOT) blocked the melatonin concentration-dependent inhibitory effect on cAMP accumulation in the retinas initiating differentiation (E7-E9), suggesting a tight binding between melatonin and their receptors. However, 4-P-PDOT competitively reverted the melatonin effect on cAMP stimulated by forskolin during synaptogenesis stages. Together, the melatonin effect on cAMP levels in chick retina, which is mainly through melatonin receptors, is depending on the developmental period observed, probably taking part in the mechanisms surrounding the melatonin action on neuronal differentiation.
Sampaio
Lucia de Fatima Sobral
Lde F
Laboratório de Bioquímica do Desenvolvimento do Sistema Nervoso, Instituto de Ciências Biológicas, Universidade Federal do Pará, 1 Belém, PA, Brazil. lsampaio@ufpa.br
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002642:Chick Embryo; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D008550:Melatonin / Q000494:pharmacology / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D044123:Receptor, Melatonin, MT2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D012160:Retina / Q000187:drug effects / Q000196:embryology* / Q000378:metabolism*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D014363:Tryptamines / Q000494:pharmacology
C114459:4-phenyl-2-propionamidotetraline; D010726:Phosphodiesterase Inhibitors; D044123:Receptor, Melatonin, MT2; D013764:Tetrahydronaphthalenes; D014363:Tryptamines; C057154:luzindole; D005576:Colforsin; D000242:Cyclic AMP; D008550:Melatonin